ASTELLAS PHARMA INC Stock News

Japan's Astellas Pharma said on Monday the U.S. Food and Drug Administration (FDA) has declined to approve its experimental drug to treat a type of gastric cancer, citing issues related to a third-par

The European Commission has approved Astellas Pharma's fezolinetant, a non-hormonal treatment for managing moderate-to-severe vasomotor symptoms (VMS) like hot flashes and night sweats in menopausal w

Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call November 1, 2023 3:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy & Relations Atsushi Kitamura - Chief Fin

ALPMY, BTDPY and ALRS have been added to the Zacks Rank #5 (Strong Sell) List on October 2, 2023.

ALPMY, ASH and DHC have been added to the Zacks Rank #5 (Strong Sell) List on September 26, 2023.

ALPMY, CBRE and FMAO have been added to the Zacks Rank #5 (Strong Sell) List on September 18, 2023.

Japan-based Astellas Pharma on Wednesday withdrew a lawsuit filed against the U.S. government, days after its prostate cancer drug was spared from the first list of drugs that will be subject to Medic

Major pharmaceutical companies including Johnson & Johnson NYSE: JNJ, Novartis AG NYSE: NVS, Bristol-Myers Squibb (NYSE: BMY), Merck & Co., Inc. NYSE: MRK, Eli Lilly & Co. NYSE: LLY and Amgen In

ALPMY, CYRX and DRCT have been added to the Zacks Rank #5 (Strong Sell) List on August 21, 2023.

Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2023 Earnings Conference Call August 1, 2023 4:00 AM ET Company Participants Hiromitsu Ikeda - Corporate Head, Advocacy and Relations Naoki Okamura - Representati

You have probably seen coverage of a renewed interest in Japanese stocks among well-known investors, including Berkshire Hathaway BRK.B, -0.57% CEO Warren Buffett. But Krishna Mohanraj, who runs a hig

Foreign investors and businesspeople with exposure to China are becoming increasingly unnerved. And for good reason.

Naoki Okamura, chief executive officer of Japanese drugmaker Astellas Pharma Inc., discusses his company's decision to acquire Iveric Bio Inc., a developer of drugs to treat age-related blindness, f

Iveric Bio Inc shares climbed 16% to $38.01 on Monday after the US drugmaker agreed to be acquired by Japan's Astellas Pharma for $40 per share in cash or total consideration of about $5.9 billion.

Astellas Pharma snapped up Iveric Bio for $5.9 billion in cash, the companies said Monday in an announcement that sent ISEE stock flying. The post Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion